| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.01 (0%) | 🛒 Add to cart |
| 60 | $1.07 | $82.03 $64.02 (22%) | 🛒 Add to cart |
| 90 | $0.97 | $123.04 $87.03 (29%) | 🛒 Add to cart |
| 120 | $0.93 | $164.06 $111.04 (32%) | 🛒 Add to cart |
| 180 | $0.87 | $246.08 $157.05 (36%) | 🛒 Add to cart |
| 270 | $0.84 | $369.12 $227.08 (38%) | 🛒 Add to cart |
| 360 | $0.83
Best per pill | $492.17 $297.10 (40%) | 🛒 Add to cart |
Similar products
More info:
bupropion
Bupropion is an atypical antidepressant belonging to the norepinephrine-dopamine reuptake inhibitor (NDRI) class, chemically distinct from SSRIs and SNRIs. Initially approved for depression in 1985, it has since gained indications for smoking cessation and seasonal affective disorder. Its unique mechanism—avoiding serotonin pathways—makes it particularly valuable for patients who can’t tolerate sexual side effects or weight gain associated with other antidepressants. We’ve been using it in our practice since the late 90s, and I still remember our initial skepticism about an antidepressant that didn’t touch serotonin.
Bupron SR: Sustained Mood Stabilization and Smoking Cessation - Evidence-Based Review
Bupron SR is a sustained-release formulation of bupropion hydrochloride, primarily indicated as an antidepressant and smoking cessation aid. This monograph examines the extended-release mechanism that provides stable plasma concentrations over 24 hours, distinguishing it from immediate-release formulations through its polymer-based matrix system. The SR technology represents a significant advancement in maintaining therapeutic levels while minimizing peak-trough fluctuations that often cause side effects. 1. Introduction: What is Bupron SR? Its Role in Modern Medicine Bupron SR belongs to the aminoketone class of antidepressants, chemically unrelated to SSRIs or tricyclics.
Celexa: Effective Symptom Relief for Major Depressive Disorder - Evidence-Based Review
Celexa, known generically as citalopram hydrobromide, is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication approved by the FDA for the treatment of major depressive disorder (MDD) in adults. It functions by increasing serotonin levels in the brain, which helps improve mood, sleep, appetite, and energy level. Celexa is one of the most widely prescribed antidepressants globally due to its efficacy and relatively favorable side effect profile compared to older antidepressants.
champix
Champix – that name still evokes such strong memories from my smoking cessation clinic days. It’s not just another nicotine replacement therapy; it’s a partial nicotinic receptor agonist that fundamentally changes how patients experience smoking cessation. I remember when we first started prescribing it back in 2006, the excitement among our pulmonary team was palpable – finally, something that addressed the neurobiological basis of addiction rather than just managing withdrawal symptoms.
contrave
Contrave represents one of the more interesting pharmacological approaches to chronic weight management we’ve seen in recent years. It’s not another stimulant-based appetite suppressant or surgical alternative, but rather a combination product that works on the brain’s reward and craving pathways. When I first reviewed the clinical trial data back in 2014, I was skeptical—combining a noradrenaline-dopamine reuptake inhibitor with an opioid receptor antagonist seemed like an odd pairing for weight loss.
eldepryl
Eldepryl, known generically as selegiline hydrochloride, represents one of the more fascinating selective monoamine oxidase-B inhibitors we’ve used in movement disorder clinics since the 1980s. Originally developed as an antidepressant, its Parkinson’s disease applications really opened up new treatment paradigms that still influence how we approach dopaminergic therapy today. The transition from a non-selective MAO inhibitor to this selective MAO-B version was actually quite revolutionary in terms of reducing those infamous dietary restrictions and opening up combination therapy possibilities.
emsam
Emsam represents one of the more elegant solutions in psychopharmacology – a transdermal monoamine oxidase inhibitor (MAOI) patch delivering selegiline for major depressive disorder. What makes it clinically fascinating isn’t just the mechanism, but how it bypasses the traditional limitations of oral MAOIs while maintaining their robust antidepressant efficacy. I’ve been working with this delivery system since its FDA approval in 2006, and the evolution in both patient response and our understanding of its nuances has been remarkable.
flibanserin
Flibanserin is a centrally-acting, multifunctional serotonin receptor agonist and antagonist that was initially investigated as an antidepressant before its approval for a very specific indication in premenopausal women. It’s not your typical supplement or device - it’s a prescription medication with a complex neuropharmacological profile that requires careful patient selection and monitoring. What’s fascinating is how it diverges from conventional approaches to female sexual dysfunction, working not on hormonal pathways but rather on the brain’s neurotransmitter systems to modulate sexual desire.
Fluoxetine: Evidence-Based Treatment for Depression and Anxiety Disorders - Comprehensive Review
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication, not a dietary supplement or medical device. It’s prescribed primarily for major depressive disorder, obsessive-compulsive disorder, panic disorder, and bulimia nervosa. This compound works by increasing serotonin levels in the brain, which helps regulate mood, appetite, and sleep patterns. I remember when we first started working with fluoxetine back in the early 90s - the excitement was palpable but so was the skepticism.